Twenty-Four Months Follow-Up of Intravitreal Bevacizumab Injection versus Intravitreal Triamcinolone Acetonide Injection for the Management of Persistent Non-Infectious Uveitic Cystoid Macular Edema

Andrés F. Lasave, Ariel Schlaen, David G. Zeballos, Manuel Díaz-Llopis, Cristóbal Couto, Wael M. El-Haig, J Fernando Arevalo

Research output: Contribution to journalArticlepeer-review

Abstract

Purpose: To report the efficacy of intravitreal bevacizumab (IVB) injection versus intravitreal triamcinolone acetonide (IVT) for persistent non-infectious uveitic cystoid macular edema (CME). Methods: Interventional retrospective comparative case series evaluated 37 consecutive patients (44 eyes) with completely controlled uveitis and recalcitrant CME. Patients received repeated injections of 1.25 mg of IVB or 4 mg of IVT. Results: Best-corrected visual acuity (BCVA) at baseline and 24 months was logMAR 1 and 0.8 respectively, in the IVB group (p = 0.002) and; logMAR of 1.1 and 0.6, in the IVT group (p = 0.001). Central macular thickness at baseline and 24 months was 399.2 µm and 333.7 µm (p < 0.0009), respectively, for the IVB group and; 464.4 µm and 316.5 µm in the IVT group (p = 0.044). Postoperatively, IOP increased in the IVT group. Conclusions: Repeated injections with IVT improve BCVA as effectively as repeated injections with IVB in the long-term management of persistent uveitic CME.

Original languageEnglish (US)
Pages (from-to)1-9
Number of pages9
JournalOcular Immunology and Inflammation
DOIs
StateAccepted/In press - Nov 19 2017

Keywords

  • Bevacizumab
  • Intravitreal Injection
  • Triamcinolone Acetonide
  • Uveitic Cystoid Macular Edema

ASJC Scopus subject areas

  • Immunology and Allergy
  • Ophthalmology

Fingerprint Dive into the research topics of 'Twenty-Four Months Follow-Up of Intravitreal Bevacizumab Injection versus Intravitreal Triamcinolone Acetonide Injection for the Management of Persistent Non-Infectious Uveitic Cystoid Macular Edema'. Together they form a unique fingerprint.

Cite this